financetom
Business
financetom
/
Business
/
Applied Materials Fiscal Q1 Non-GAAP Earnings, Revenue Rise; Sets Fiscal Q2 Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Applied Materials Fiscal Q1 Non-GAAP Earnings, Revenue Rise; Sets Fiscal Q2 Guidance
Feb 13, 2025 1:51 PM

04:14 PM EST, 02/13/2025 (MT Newswires) -- Applied Materials ( AMAT ) reported fiscal Q1 non-GAAP earnings late Thursday of $2.38 per diluted share, up from $2.13 a year earlier.

Analysts polled by FactSet expected $2.28.

Revenue for the quarter ended Jan. 26 was $7.17 billion, up from $6.71 billion a year earlier.

Analysts surveyed by FactSet expected $7.15 billion.

The company said it expects fiscal Q2 non-GAAP diluted EPS of $2.30, plus or minus $0.18, on revenue of $7.10 billion, plus or minus $400 million. Analysts surveyed by FactSet expect $2.29 and $7.21 billion, respectively.

Shares of the company were down 3.6% in recent after-hours activity.

Price: 177.70, Change: -6.57, Percent Change: -3.57

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Organon CEO Kevin Ali to resign after probe into contraceptive sales
Organon CEO Kevin Ali to resign after probe into contraceptive sales
Oct 27, 2025
Oct 27 (Reuters) - Organon said on Monday CEO Kevin Ali will resign from his role, after an internal investigation into sales of its Nexplanon contraceptive implant to wholesalers pointed to improper practices. An audit committee found certain U.S. wholesalers were asked to purchase more Nexplanon than needed at the end of several quarters between 2022 and 2025. While the...
Intellia Therapeutics Pauses Dosing in Phase 3 Trials After Grade 4 Liver Transaminases Reported in Participant
Intellia Therapeutics Pauses Dosing in Phase 3 Trials After Grade 4 Liver Transaminases Reported in Participant
Oct 27, 2025
08:01 AM EDT, 10/27/2025 (MT Newswires) -- Intellia Therapeutics ( NTLA ) said Monday it has paused patient dosing and screening for its two phase 3 clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy and polyneuropathy, respectively, after a patient was reported with Grade 4 liver transaminases and increased total bilirubin after dosage with the drug. The...
BTU Dixie East Project Approved
BTU Dixie East Project Approved
Oct 27, 2025
VANCOUVER, BC / ACCESS Newswire ( ACCS ) / October 27, 2025 / BTU METALS CORP. ( BTUMF ) (BTU or the Company) (OTCQB:BTUMF) is pleased to announce the acquisition of the 100% interest in the newly secured Dixie East Project, a large and strategically located land package immediately east of Kinross Gold's ( KGCRF ) world-renowned Great Bear Dixie...
Johnson & Johnson Says 2-Year Data for Tremfya in Crohn's Disease Shows Durable Remission
Johnson & Johnson Says 2-Year Data for Tremfya in Crohn's Disease Shows Durable Remission
Oct 27, 2025
08:01 AM EDT, 10/27/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Monday that long-term extensions of its phase 3 studies showed that its drug, Tremfya, maintained high rates of clinical and endoscopic remission in adults with moderately to severely active Crohn's disease through two years. The drugmaker said the studies evaluated patients who received either subcutaneous or...
Copyright 2023-2025 - www.financetom.com All Rights Reserved